An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager

Bispecific T‐cell engagers (Bi‐TCEs) have revolutionized the treatment and management of both hematological and solid tumor indications with opportunities to become best‐in‐class therapeutics for cancer. However, defining the dose and dosing regimen for the first‐in‐human (FIH) studies of Bi‐TCEs ca...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical pharmacology and therapeutics 2025-01, Vol.117 (1), p.225-231
Hauptverfasser:	Zhou, Di, Kischel, Roman, Stienen, Sabine, Townsley, Danielle, Sternjak, Alexander, Lutteropp, Michael, Bailis, Julie, Friedrich, Matthias, Rattel, Benno, Mehta, Khamir, Upreti, Vijay V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - adverse effects Antibodies, Bispecific - pharmacokinetics Antibodies, Bispecific - pharmacology Antibodies, Bispecific - therapeutic use Dose-Response Relationship, Drug Humans Neoplasms - drug therapy Neoplasms - immunology T-Lymphocytes - drug effects T-Lymphocytes - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!